SIM0532 (Simcere Pharmaceutical Group)

SIM0532 is an investigational antibody-drug conjugate (ADC) developed by Simcere Pharmaceutical and its subsidiary Shandong Simcere Medgenn. It is designed as a "Pan-Folate Receptor" (Pan-FR) targeted therapy, binding to multiple isoforms of the folate receptor, such as Folate Receptor alpha (FRα) and Folate Receptor beta (FRβ), which are frequently overexpressed in various solid tumors. The drug consists of a monoclonal antibody conjugated to a cytotoxic payload, typically a topoisomerase I inhibitor, via a cleavable linker. By targeting multiple isoforms, SIM0532 aims to provide broader anti-tumor activity and overcome resistance mechanisms associated with single-isoform targeting. While some pipeline visualizations have associated the SIM0532 code with anti-infective research (potentially involving viral polymerases or influenza), its primary clinical development focus is in oncology for the treatment of advanced solid tumors.

Other names

PanFRML